1. Technical Field
The present disclosure relates generally to a wound dressing for treating an open wound with a vacuum wound therapy treatment. In particular, the disclosure relates to a dressing having a portal member providing a connection to a vacuum system such that a reservoir over the wound may be evacuated.
2. Background of Related Art
The body's natural wound healing process is a complex series of events beginning at the moment of injury. Initially the body reacts by delivering proteins and other factors to the wound through the blood stream to minimize the damage. Blood clots to prevent blood loss while cells engulf bacteria and debris to carry it away from the wound site. Next, the body begins to repair itself in a stage of healing often referred to as the proliferative phase. This phase is characterized by the deposition granulation tissue in the wound bed. Granulation tissue provides a base structure over which cells may migrate inwardly from the periphery to close the wound. Finally the process ends as collagen gives strength to new tissue over time often forming a scar.
One technique for promoting the natural healing process, particularly, but not exclusively during the proliferative phase, is known as vacuum wound therapy (VWT). Application of a reduced pressure, e.g. sub-atmospheric, to a localized reservoir over a wound has been found to assist in closing the wound. The reduced pressure may be effective to promote blood flow to the area to stimulate the formation of granulation tissue and the migration of healthy tissue over the wound by the natural process. Also a reduced pressure may assist in removing fluids exuding from the wound, which may inhibit bacterial growth. This technique has proven effective for chronic or non-healing wounds, but has also been used in for other purposes such as post-operative wound care.
The general VWT protocol provides for the introduction of an absorbent filler material, such as non-reticulated foams, non-woven fabrics, or gauze, into the wound to absorb exudates. The wound and the absorbent filler material may then be overlaid by a flexible cover layer such as a polymeric film, for example, to establish a vacuum reservoir over the wound where a reduced pressure may be applied by individual or cyclic evacuation procedures. To allow the reduced pressure to be maintained over time, the cover layer may include an adhesive periphery that forms a substantially fluid tight seal with the healthy skin surrounding the wound.
Although some procedures may employ a micro-pump contained within the vacuum reservoir, most VWT treatments apply a reduced pressure using an external vacuum source. Thus, fluid communication between the vacuum source and the reservoir must be established. To this end, a cover layer will often include a connector or portal member to which air hoses from an external vacuum system may be connected.
An aspect of concern in a VWT treatment is the migration of the filler material and wound exudates in the direction of airflow when the reduced pressure is applied. These substances may be deposited on surfaces within a portal member, for example, and over time cause the obstruction or complete occlusion of these portal members. This phenomenon may limit the level of exudate flow from the wound area, or may even prohibit the application of a reduced pressure to the wound area, thus limiting or defeating the effectiveness of the VWT treatment. Accordingly, a need exists for a dressing suitable for use in a VWT procedure.
The present disclosure describes a wound dressing for use in a vacuum wound therapy treatment. The wound dressing includes a backing layer for positioning over a wound to define a reservoir in which a reduced pressure may be maintained over the wound. A portal member is affixed to the backing layer such that an ambient surface of the portal member may be fluidly isolated from a reservoir surface of the portal member. The backing layer defines a boundary between the ambient surface and the reservoir surface when the backing layer is positioned over a wound. The portal member comprises a primary port extending between an opening in the ambient surface and a primary aperture in the reservoir surface. The opening is adapted for connection to a suction device and the primary aperture is adapted for establishing fluid communication with the reservoir. The portal member further comprises at least one supplemental port establishing fluid communication between the primary port and a supplemental aperture in the reservoir surface. The supplemental aperture is distinct and substantially spaced from the primary aperture.
The portal member may include a plurality of supplemental ports extending radially outwardly from the primary port. The primary and supplemental apertures may be distributed substantially over the entire reservoir surface. The may be molded from a flexible polymeric or elastomeric material and may include an attachment flange adapted for connection of an adhesively coated film.
The backing layer of the wound dressing may comprise a flexible polymeric membrane. The backing layer may include an adhesive coating adapted to affix the backing layer over the wound and to provide a substantially fluid tight seal around the perimeter of the wound. The adhesive coating may be interrupted such that an intermediate portion of the backing layer remains uncoated.
According to a further aspect of the disclosure, a vacuum wound therapy system includes a contact layer and an absorbent filler positioned in a wound bed, and a portal member affixed to a backing layer positioned over the wound bed to define a vacuum reservoir. The portal member includes a primary port extending between an opening in an ambient surface and a primary aperture in a reservoir surface, and at least one supplemental port extending between the primary port and a supplemental aperture distinct and substantially spaced from the primary aperture.
The contact layer may be formed from a conical apertured film to promote unidirectional flow of exudates from the wound. The absorbent filler material may include a single strand of a polyolefin filament. Also, a vacuum system in fluid communication with the vacuum reservoir may include a vacuum source, a collection canister and a one-way valve.
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure and, together with the detailed description of the embodiments given below, serve to explain the principles of the disclosure.
The wound dressing of the present disclosure promotes healing of a wound by providing a reservoir over the wound where a reduced pressure may be maintained. The reservoir subjects the wound to a sub-atmospheric pressure to effectively draw wound fluid, including liquid exudates, from the wound without the continuous use of a vacuum pump. Hence, vacuum pressure may be applied once, or in varying intervals depending on the nature and severity of the wound. The use of a wound dressing in this manner has been found to promote healing by reducing the probability of infection, stimulating the deposition of granulation tissue and other beneficial processes. The wound dressing of the present disclosure includes a backing layer affixed to a portal member for enhancing the effect of a vacuum wound therapy treatment.
The attached figures illustrate exemplary embodiments of the present disclosure and are referenced to describe the embodiments depicted therein. Hereinafter, the disclosure will be described in detail by explaining the figures wherein like reference numerals represent like parts throughout the several views.
Referring initially to
Wound dressing 16 generally includes a contact layer 34, filler 38 and a cover layer 40. Cover layer 40 includes a backing layer 44 and a portal member 46. Portal member 46 is configured to establish fluid communication between vacuum reservoir 14 and vacuum system 12 by providing an interface for a suction device such as vacuum tube 24. Each layer of wound dressing 16 is described in greater detail below.
Contact layer 34 may be sufficiently conformable to be positioned in direct contact with an irregularly shaped surface of a wound bed “w.” A thin film of polyethylene or other suitable non-adherent material may form the contact layer 34 to limit the adherence of filler 38 and other substances to the wound “w.” Apertures or perforations in the film permit fluids to pass through the contact layer 34, allowing for the sub-atmospheric pressure to penetrate into the wound “w” and for exudates to flow freely out of the wound “w.” By selecting an appropriate film material, the passage of wound exudate through contact layer 34 may be controlled so as to be substantially unidirectional to prevent wound exudate from flowing back into the wound. To promote a unidirectional flow, a conical apertured film, such as VENTEX™ by Kendall Corp., a division of Covidien, or apertured films by Tredegar Film Products of Richmond, Va., may be selected for forming contact layer 34. Unidirectional flow of exudates may also be promoted by the selection of other materials including a lamination of layers having varying absorptive characteristics. One exemplary material, which may be used as a contact layer is sold under the trademark XEROFLO® by Kendall Corp., a division of Covidien.
Filler 38 may be arranged over contact layer 34 to fill wound “w” to the level of the surrounding healthy skin “s.” An absorbent material such as non-woven gauze or reticulated foam may be used for filler 38 to trap any exudate that migrates through contact layer 34. An antimicrobial dressing sold under the trakemark KERLIX® by Kendall Corp., a division of Covidien, may be suitable for use as filler 38. To prevent adhesion to the wound “w,” the filler 38 may also comprise a material configured such that any stray fibers do not tend to protrude through apertures of contact layer 34 where they may become engulfed by newly forming granulation tissue. One particular type of material exhibiting this characteristic is often referred to as “tow.” The manufacturing process for synthetic fibers often includes an extrusion of an indeterminate length of continuous filaments, which are spun together to form fibers. It is the continuous lengths of un-spun filaments which are referred to as tow. A single length of tow formed from a hydrophobic material such as polyolefin may be laid in the wound bed “w” to form filler 38. This arrangement allows for a complete removal of filler 38 when the dressing 16 is changed without re-injuring the wound “w.”
Cover layer 40 may be supplied as a single unit including both backing layer 44 and portal member 46, or alternatively, these items may be provided individually and assembled at the time of installation over the wound “w.” Cover layer 40 may be placed over the wound “w” enclosing the contact layer 34 and filler 38 therein.
Backing layer 44 may be formed from a flexible polymeric membrane or film to serve as a fluid barrier to allow for a sub-atmospheric pressure to be established in vacuum reservoir 14, and also as a microbial barrier preventing contaminants from entering the wound area. For example, backing layer 44 may comprise a polyurethane film having a thickness from about 0.8 mils to about 1.0 mils. Preferably, the backing layer 44 is formed from a moisture vapor permeable membrane to promote the exchange of oxygen and moisture vapor between the wound site and the atmosphere. One exemplary material is a transparent membrane sold under the trade name POLYSKIN® II by Kendall Corp., a division of Covidien. Other materials which may be suitable for use in a backing layer include the thin films marketed under the names TEGADERM™ by 3M of St. Paul, Minn. and OPSITE™ by Smith and Nephew PLC of London, UK.
The backing layer 44 of cover layer 40 is adapted to extend laterally beyond the perimeter of the wound bed “w” so as to contact the healthy skin “s” to form a seal thereto. To form the seal, backing layer 44 may be equipped with an adhesive coating on all, or any appropriate portion of a wound facing side. The adhesive coating may comprise, for example, a medical-grade, pressure-sensitive adhesive adapted to provide a fluid-tight and bacteria-tight seal around the wound “w.” Thus exudate cannot escape through the edges of the dressing 16 and external air and contaminants may not enter the wound area. To provide such a seal, the adhesive coating may, for example, be in the range from about 1 mil to about 10 mils thick. In general, a high peal-strength adhesive may be used to resist inadvertent lift-off, roll or “flagging,” i.e., a failure of the dressing to adhere to itself, at the edges of the cover layer 40. The adhesive may include, for example, those adhesives included with the dressing sold under the trademark ULTEC® Hydrocolloid by Kendall Corp., a division of Covidien.
Backing layer 44 includes a connective region 50 to permit of connection of portal member 46. Connective region 50 receives a reservoir surface 54 of portal member 46 to fluidly isolate the reservoir surface 54 from an ambient surface 56 on the portal member 46 except through portal member 46. As illustrated in
Backing layer 44 may include an interrupted adhesive coating such that only the portions of backing layer 44 forming a seal are coated. For example, backing layer 44 may include a band of adhesive coating around the periphery to form a seal with the skin “s,” and another band near the connective region 50 to form a seal with the portal member 46. An intermediate portion of backing layer 44 may remain uncoated to limit the adherence of backing layer 44 to the filler 38, contact layer 34 or other surfaces. Such an arrangement may facilitate removal of the dressing 16 without re-injuring the wound “w.”
Referring now to
Branching from primary port 70 is a radial array of supplemental ports 72 extending to reservoir surface 54. Each of the supplemental ports 72 terminates at a supplemental aperture 74 distinct from and substantially spaced from primary aperture 64. Any number, distribution and arrangement of supplemental ports 72 may be included to distribute supplemental openings 74 over the reservoir surface 54. As
Referring now to
Evacuating the reservoir 14 may impart a tendency for filler material 38 and wound exudate to migrate in the direction of airflow. This tendency for migration may result in the obstruction or occlusion of one or more of the primary and supplemental ports 70, 72. However, because portal member 46 may include many apertures 64, 74 distributed over the entire area covered by the portal member 46, the effectiveness of the VWT procedure may persist. If one of the apertures 64, 74 becomes clogged, fluids will be drawn to another one of the apertures 64, 74 that is distinct and substantially spaced from the clogged aperture 64, 74.
Referring now to
Portal member 46a includes a radial array of supplemental ports 72a such that apertures 64a, 74a may be distributed substantially over the entire reservoir surface 54a. This arrangement provides a means of keeping a collection area of the port 46a exposed to as much of the dressing 16a as possible.
Although the foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity or understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.
Number | Name | Date | Kind |
---|---|---|---|
1585104 | Montgomery | May 1926 | A |
2736317 | Alexander | Feb 1956 | A |
3042041 | Jascalevich | Jul 1962 | A |
3568675 | Harvey | Mar 1971 | A |
3572340 | Lloyd et al. | Mar 1971 | A |
3874387 | Barbieri | Apr 1975 | A |
3880164 | Stepno | Apr 1975 | A |
4080970 | Miller | Mar 1978 | A |
4164027 | Bonnie et al. | Aug 1979 | A |
4231357 | Hessner | Nov 1980 | A |
4261363 | Russo | Apr 1981 | A |
4360015 | Mayer | Nov 1982 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4468219 | George et al. | Aug 1984 | A |
4508256 | Radel et al. | Apr 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4553967 | Ferguson et al. | Nov 1985 | A |
4561435 | McKnight et al. | Dec 1985 | A |
4569674 | Phillips et al. | Feb 1986 | A |
4579120 | MacGregor | Apr 1986 | A |
4614183 | McCracken et al. | Sep 1986 | A |
4784653 | Bolton et al. | Nov 1988 | A |
4807625 | Singleton | Feb 1989 | A |
4906240 | Reed et al. | Mar 1990 | A |
4921492 | Schultz et al. | May 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4980226 | Hellgren et al. | Dec 1990 | A |
5009224 | Cole | Apr 1991 | A |
5056510 | Gilman | Oct 1991 | A |
5060642 | Gilman | Oct 1991 | A |
5088483 | Heinecke | Feb 1992 | A |
5100395 | Rosenberg | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5106362 | Gilman | Apr 1992 | A |
5112323 | Winkler et al. | May 1992 | A |
5134007 | Reising et al. | Jul 1992 | A |
5147698 | Cole | Sep 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5152757 | Eriksson | Oct 1992 | A |
5160315 | Heinecke et al. | Nov 1992 | A |
5160334 | Billings et al. | Nov 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5230496 | Shillington et al. | Jul 1993 | A |
5244457 | Karami et al. | Sep 1993 | A |
5263922 | Sova et al. | Nov 1993 | A |
5300054 | Feist et al. | Apr 1994 | A |
5304161 | Noel et al. | Apr 1994 | A |
5308313 | Karami et al. | May 1994 | A |
5366451 | Levesque | Nov 1994 | A |
5391161 | Hellgren et al. | Feb 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5439458 | Noel et al. | Aug 1995 | A |
5447492 | Cartmell et al. | Sep 1995 | A |
5486167 | Dragoo et al. | Jan 1996 | A |
5520629 | Heinecke et al. | May 1996 | A |
5525407 | Yang | Jun 1996 | A |
5527923 | Klingler et al. | Jun 1996 | A |
5531855 | Heinecke et al. | Jul 1996 | A |
5549584 | Gross | Aug 1996 | A |
5593750 | Rothrum et al. | Jan 1997 | A |
5599289 | Castellana | Feb 1997 | A |
5613942 | Lucast et al. | Mar 1997 | A |
5618278 | Rothrum | Apr 1997 | A |
5624423 | Anjur et al. | Apr 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5637093 | Hyman et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5678564 | Lawrence et al. | Oct 1997 | A |
5695846 | Lange et al. | Dec 1997 | A |
5738642 | Heinecke et al. | Apr 1998 | A |
5797844 | Yoshioka et al. | Aug 1998 | A |
5797894 | Cadieux et al. | Aug 1998 | A |
5894608 | Birbara | Apr 1999 | A |
5914282 | Dunshee et al. | Jun 1999 | A |
5968001 | Freeman | Oct 1999 | A |
6071267 | Zamierowski | Jun 2000 | A |
6117111 | Fleischmann | Sep 2000 | A |
6121508 | Bischof et al. | Sep 2000 | A |
6142982 | Hunt et al. | Nov 2000 | A |
6169224 | Heinecke et al. | Jan 2001 | B1 |
6264976 | Heinecke et al. | Jul 2001 | B1 |
6291050 | Cree et al. | Sep 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6398767 | Fleischmann | Jun 2002 | B1 |
6406447 | Thrash et al. | Jun 2002 | B1 |
6420622 | Johnston et al. | Jul 2002 | B1 |
6436432 | Heinecke et al. | Aug 2002 | B2 |
6461467 | Blatchford et al. | Oct 2002 | B2 |
6479073 | Lucast et al. | Nov 2002 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6566575 | Stickels et al. | May 2003 | B1 |
6607799 | Heinecke et al. | Aug 2003 | B1 |
6626891 | Ohmstede | Sep 2003 | B2 |
6648862 | Watson | Nov 2003 | B2 |
6685681 | Lockwood et al. | Feb 2004 | B2 |
6685682 | Heinecke et al. | Feb 2004 | B1 |
6695824 | Howard et al. | Feb 2004 | B2 |
6752794 | Lockwood et al. | Jun 2004 | B2 |
6755807 | Risk, Jr. et al. | Jun 2004 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
6838589 | Liedtke et al. | Jan 2005 | B2 |
6855135 | Lockwood et al. | Feb 2005 | B2 |
6867342 | Johnston et al. | Mar 2005 | B2 |
6878857 | Chihani et al. | Apr 2005 | B1 |
6903243 | Burton | Jun 2005 | B1 |
6936037 | Bubb et al. | Aug 2005 | B2 |
6951553 | Bubb et al. | Oct 2005 | B2 |
6994702 | Johnson | Feb 2006 | B1 |
6994904 | Joseph et al. | Feb 2006 | B2 |
7004915 | Boynton et al. | Feb 2006 | B2 |
7005143 | Abuelyaman et al. | Feb 2006 | B2 |
7070580 | Nielsen | Jul 2006 | B2 |
7070584 | Johnson et al. | Jul 2006 | B2 |
7108683 | Zamierowski | Sep 2006 | B2 |
7117869 | Heaton | Oct 2006 | B2 |
7128735 | Weston | Oct 2006 | B2 |
7182758 | McCraw | Feb 2007 | B2 |
7183454 | Rosenberg | Feb 2007 | B1 |
7195624 | Lockwood et al. | Mar 2007 | B2 |
7198046 | Argenta et al. | Apr 2007 | B1 |
7216651 | Argenta et al. | May 2007 | B2 |
7273054 | Heaton et al. | Sep 2007 | B2 |
7276247 | Fansler et al. | Oct 2007 | B2 |
7279612 | Heaton et al. | Oct 2007 | B1 |
7285576 | Hyde et al. | Oct 2007 | B2 |
7316672 | Hunt et al. | Jan 2008 | B1 |
7338482 | Lockwood et al. | Mar 2008 | B2 |
7381859 | Hunt et al. | Jun 2008 | B2 |
7381860 | Gudnason et al. | Jun 2008 | B2 |
7438705 | Karpowicz et al. | Oct 2008 | B2 |
7442849 | Heinecke | Oct 2008 | B2 |
7485112 | Karpowicz et al. | Feb 2009 | B2 |
7503910 | Adahan | Mar 2009 | B2 |
7524315 | Blott et al. | Apr 2009 | B2 |
7534927 | Lockwood et al. | May 2009 | B2 |
7569742 | Haggstrom et al. | Aug 2009 | B2 |
7585554 | Johnson et al. | Sep 2009 | B2 |
7586019 | Oelund et al. | Sep 2009 | B2 |
7608066 | Vogel | Oct 2009 | B2 |
7625362 | Boehringer et al. | Dec 2009 | B2 |
7645269 | Zamierowski | Jan 2010 | B2 |
7651484 | Heaton et al. | Jan 2010 | B2 |
7670323 | Hunt et al. | Mar 2010 | B2 |
7678102 | Heaton | Mar 2010 | B1 |
7686785 | Boehringer et al. | Mar 2010 | B2 |
7699823 | Fink | Apr 2010 | B2 |
7699830 | Martin | Apr 2010 | B2 |
7723560 | Lockwood et al. | May 2010 | B2 |
7745681 | Ferguson | Jun 2010 | B1 |
7754937 | Boehringer et al. | Jul 2010 | B2 |
7758554 | Lina et al. | Jul 2010 | B2 |
7759537 | Bishop et al. | Jul 2010 | B2 |
7759539 | Shaw et al. | Jul 2010 | B2 |
7779625 | Joshi et al. | Aug 2010 | B2 |
7781639 | Johnston et al. | Aug 2010 | B2 |
7790945 | Watson, Jr. | Sep 2010 | B1 |
7790946 | Mulligan | Sep 2010 | B2 |
7794438 | Henley et al. | Sep 2010 | B2 |
7794450 | Blott et al. | Sep 2010 | B2 |
7815616 | Boehringer et al. | Oct 2010 | B2 |
7862718 | Doyen et al. | Jan 2011 | B2 |
7880050 | Robinson et al. | Feb 2011 | B2 |
7883494 | Martin | Feb 2011 | B2 |
7896864 | Lockwood et al. | Mar 2011 | B2 |
7909805 | Weston | Mar 2011 | B2 |
7942866 | Radl et al. | May 2011 | B2 |
7951124 | Boehringer et al. | May 2011 | B2 |
7964766 | Blott et al. | Jun 2011 | B2 |
7976533 | Larsson | Jul 2011 | B2 |
7981098 | Boehringer et al. | Jul 2011 | B2 |
8002313 | Singh et al. | Aug 2011 | B2 |
8021347 | Vitaris et al. | Sep 2011 | B2 |
8057449 | Sanders et al. | Nov 2011 | B2 |
8061360 | Locke et al. | Nov 2011 | B2 |
8062272 | Weston | Nov 2011 | B2 |
8083712 | Biggie et al. | Dec 2011 | B2 |
8105295 | Blott et al. | Jan 2012 | B2 |
8152785 | Vitaris | Apr 2012 | B2 |
8235955 | Blott et al. | Aug 2012 | B2 |
8257327 | Blott et al. | Sep 2012 | B2 |
8267908 | Coulthard | Sep 2012 | B2 |
8348910 | Blott et al. | Jan 2013 | B2 |
8372049 | Jaeb et al. | Feb 2013 | B2 |
8430867 | Robinson et al. | Apr 2013 | B2 |
8444612 | Patel et al. | May 2013 | B2 |
8506554 | Adahan | Aug 2013 | B2 |
8529548 | Blott et al. | Sep 2013 | B2 |
8545466 | Andresen et al. | Oct 2013 | B2 |
20010031943 | Urie | Oct 2001 | A1 |
20020002209 | Mork | Jan 2002 | A1 |
20020065494 | Lockwood et al. | May 2002 | A1 |
20020115952 | Johnson et al. | Aug 2002 | A1 |
20020161346 | Lockwood et al. | Oct 2002 | A1 |
20020182246 | Oyaski | Dec 2002 | A1 |
20030225347 | Argenta et al. | Dec 2003 | A1 |
20040030304 | Hunt et al. | Feb 2004 | A1 |
20040039415 | Zamierowski | Feb 2004 | A1 |
20040064132 | Boehringer et al. | Apr 2004 | A1 |
20040073151 | Weston | Apr 2004 | A1 |
20050004534 | Lockwood et al. | Jan 2005 | A1 |
20050010153 | Lockwood et al. | Jan 2005 | A1 |
20050020955 | Sanders et al. | Jan 2005 | A1 |
20050065484 | Watson, Jr. | Mar 2005 | A1 |
20050070858 | Lockwood et al. | Mar 2005 | A1 |
20050085795 | Lockwood et al. | Apr 2005 | A1 |
20050137539 | Biggie et al. | Jun 2005 | A1 |
20050203452 | Weston et al. | Sep 2005 | A1 |
20050222527 | Miller et al. | Oct 2005 | A1 |
20050273066 | Wittmann | Dec 2005 | A1 |
20060009744 | Erdman et al. | Jan 2006 | A1 |
20060020234 | Chou et al. | Jan 2006 | A1 |
20060025727 | Boehringer | Feb 2006 | A1 |
20060036221 | Watson, Jr. | Feb 2006 | A1 |
20060041247 | Petrosenko et al. | Feb 2006 | A1 |
20060079852 | Bubb et al. | Apr 2006 | A1 |
20060100586 | Karpowicz et al. | May 2006 | A1 |
20070014837 | Johnson | Jan 2007 | A1 |
20070016152 | Karpowicz | Jan 2007 | A1 |
20070021697 | Ginther | Jan 2007 | A1 |
20070032762 | Vogel | Feb 2007 | A1 |
20070032778 | Heaton et al. | Feb 2007 | A1 |
20070038172 | Zamierowski | Feb 2007 | A1 |
20070066946 | Haggstrom et al. | Mar 2007 | A1 |
20070156104 | Lockwood et al. | Jul 2007 | A1 |
20070167927 | Hunt et al. | Jul 2007 | A1 |
20070185426 | Ambrosio | Aug 2007 | A1 |
20070185463 | Mulligan | Aug 2007 | A1 |
20070219497 | Johnson et al. | Sep 2007 | A1 |
20070233022 | Henley et al. | Oct 2007 | A1 |
20070265561 | Yeung | Nov 2007 | A1 |
20070265585 | Joshi et al. | Nov 2007 | A1 |
20070282310 | Bengtson | Dec 2007 | A1 |
20080033325 | Van der Hulst | Feb 2008 | A1 |
20080039761 | Heaton et al. | Feb 2008 | A1 |
20080103489 | Dahners | May 2008 | A1 |
20080108977 | Heaton et al. | May 2008 | A1 |
20080119802 | Riesinger | May 2008 | A1 |
20080161778 | Steward | Jul 2008 | A1 |
20080167593 | Fleischmann | Jul 2008 | A1 |
20080195017 | Robinson et al. | Aug 2008 | A1 |
20080200906 | Sanders et al. | Aug 2008 | A1 |
20080208147 | Argenta et al. | Aug 2008 | A1 |
20080215019 | Malamutmann | Sep 2008 | A1 |
20080234641 | Locke et al. | Sep 2008 | A1 |
20080243096 | Svedman | Oct 2008 | A1 |
20080281281 | Meyer et al. | Nov 2008 | A1 |
20080300578 | Freedman | Dec 2008 | A1 |
20080306456 | Riesinger | Dec 2008 | A1 |
20080312572 | Riesinger | Dec 2008 | A1 |
20090005744 | Karpowicz et al. | Jan 2009 | A1 |
20090093778 | Svedman | Apr 2009 | A1 |
20090099519 | Kaplan | Apr 2009 | A1 |
20090124988 | Coulthard | May 2009 | A1 |
20090131892 | Karpowicz et al. | May 2009 | A1 |
20090137973 | Karpowicz et al. | May 2009 | A1 |
20090157016 | Adahan | Jun 2009 | A1 |
20090171288 | Wheeler | Jul 2009 | A1 |
20090192467 | Hansen et al. | Jul 2009 | A1 |
20090192499 | Weston et al. | Jul 2009 | A1 |
20090227969 | Jaeb et al. | Sep 2009 | A1 |
20090234306 | Vitaris | Sep 2009 | A1 |
20090254053 | Svensby et al. | Oct 2009 | A1 |
20100000524 | Ohbi | Jan 2010 | A1 |
20100016767 | Jones et al. | Jan 2010 | A1 |
20100063464 | Meyer et al. | Mar 2010 | A1 |
20100063484 | Heagle | Mar 2010 | A1 |
20100069850 | Fabo | Mar 2010 | A1 |
20100106114 | Weston et al. | Apr 2010 | A1 |
20100210986 | Sanders | Aug 2010 | A1 |
20100262094 | Walton et al. | Oct 2010 | A1 |
20100262095 | Hall et al. | Oct 2010 | A1 |
20100268128 | Randolph | Oct 2010 | A1 |
20100305549 | Miller et al. | Dec 2010 | A1 |
20110213320 | Blott et al. | Sep 2011 | A1 |
20120116334 | Albert et al. | May 2012 | A1 |
20130172836 | Vess et al. | Jul 2013 | A1 |
Number | Date | Country |
---|---|---|
3907007 | Sep 1990 | DE |
20 2010 009 148 | Oct 2010 | DE |
0325771 | Sep 1993 | EP |
0392640 | Jun 1995 | EP |
0441418 | Jul 1995 | EP |
0651983 | Sep 1998 | EP |
0 774 242 | Mar 2000 | EP |
0690706 | Nov 2000 | EP |
0 674 892 | Jul 2001 | EP |
1129734 | Sep 2001 | EP |
0921775 | Dec 2001 | EP |
0 948 951 | Jun 2002 | EP |
1283702 | Feb 2003 | EP |
0 729 334 | Mar 2003 | EP |
0708620 | May 2003 | EP |
0 898 471 | May 2005 | EP |
1556120 | Jul 2005 | EP |
1660000 | May 2006 | EP |
1663062 | Jun 2006 | EP |
0982015 | Aug 2006 | EP |
2218431 | Apr 2008 | EP |
1986584 | Nov 2008 | EP |
2010065 | Jan 2009 | EP |
2079507 | Jul 2009 | EP |
2081629 | Jul 2009 | EP |
2129409 | Dec 2009 | EP |
2138139 | Dec 2009 | EP |
1652549 | Jan 2010 | EP |
2146759 | Jan 2010 | EP |
1 314 410 | Feb 2010 | EP |
2152196 | Feb 2010 | EP |
2203137 | Jul 2010 | EP |
2244217 | Oct 2010 | EP |
2244746 | Nov 2010 | EP |
2254537 | Dec 2010 | EP |
2306951 | Apr 2011 | EP |
1578477 | Sep 2011 | EP |
2 415 908 | Jan 2006 | GB |
2415908 | Jan 2006 | GB |
2431351 | Apr 2007 | GB |
WO 9403214 | Feb 1994 | WO |
WO 9421207 | Sep 1994 | WO |
WO 9423678 | Oct 1994 | WO |
WO 02070040 | Sep 2002 | WO |
WO 2004041064 | May 2004 | WO |
WO 2005009488 | Feb 2005 | WO |
WO 2005016179 | Feb 2005 | WO |
WO 2005025447 | Mar 2005 | WO |
WO 2005072789 | Aug 2005 | WO |
WO 2005079718 | Sep 2005 | WO |
WO 2005115523 | Dec 2005 | WO |
WO 2005123170 | Dec 2005 | WO |
2006105892 | Oct 2006 | WO |
WO 2007006306 | Jan 2007 | WO |
WO 2007015964 | Feb 2007 | WO |
WO 2007041642 | Apr 2007 | WO |
WO 2007062024 | May 2007 | WO |
WO 2007067685 | Jun 2007 | WO |
WO 2007085396 | Aug 2007 | WO |
WO 2007087808 | Aug 2007 | WO |
WO 2007087809 | Aug 2007 | WO |
WO 2007087811 | Aug 2007 | WO |
WO 2007092397 | Aug 2007 | WO |
WO 2007095180 | Aug 2007 | WO |
WO 2007106590 | Sep 2007 | WO |
WO 2007106591 | Sep 2007 | WO |
WO 2007133618 | Nov 2007 | WO |
WO 2007143060 | Dec 2007 | WO |
WO 2008011774 | Jan 2008 | WO |
WO 2008012278 | Jan 2008 | WO |
WO 2008013896 | Jan 2008 | WO |
WO 2008016304 | Feb 2008 | WO |
WO 2008036162 | Mar 2008 | WO |
WO 2008040020 | Apr 2008 | WO |
WO 2008041926 | Apr 2008 | WO |
WO 2008043067 | Apr 2008 | WO |
WO 2008064502 | Jun 2008 | WO |
WO 2008086397 | Jul 2008 | WO |
WO 2008100437 | Aug 2008 | WO |
WO 2008100440 | Aug 2008 | WO |
WO 2008131895 | Nov 2008 | WO |
WO 2008132215 | Nov 2008 | WO |
WO 2008135997 | Nov 2008 | WO |
WO 2008141470 | Nov 2008 | WO |
WO 2008154158 | Dec 2008 | WO |
WO 2009016603 | Feb 2009 | WO |
WO 2009016605 | Feb 2009 | WO |
WO 2009019229 | Feb 2009 | WO |
WO 2009021047 | Feb 2009 | WO |
WO 2009021353 | Feb 2009 | WO |
WO 2009034322 | Mar 2009 | WO |
WO 2009062327 | May 2009 | WO |
WO 2009068665 | Jun 2009 | WO |
WO 2009078790 | Jun 2009 | WO |
WO 2009086580 | Jul 2009 | WO |
WO 2009088925 | Jul 2009 | WO |
WO 2009111655 | Sep 2009 | WO |
Entry |
---|
European Search Report, Application No. 09152714.3, dated May 26, 2009. |
Number | Date | Country | |
---|---|---|---|
20090227968 A1 | Sep 2009 | US |